Henrietta Lacks Estate Sues Thermo Fisher over HeLa Cell Line

Attorneys for the family seek compensation for the company’s sale of cells cloned from tissue removed without consent by doctors at Johns Hopkins Hospital 70 years ago.

Written byCatherine Offord
| 3 min read
Hela cells in blue

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM,
HEITIPAVES

Attorneys representing the family of Henrietta Lacks, a Black woman whose cells were cloned, mass produced, and widely used for research after being removed from a tumor on her cervix without her knowledge in 1951, have filed a lawsuit against one of the companies that commercialized the cell line. In the suit, filed today (October 4), they argue that pharmaceutical giant Thermo Fisher Scientific continued to derive commercial benefit from so-called HeLa cells, which have been used in tens of thousands of scientific and medical studies, long after their unethical origins became known.

The attorneys further request that Thermo Fisher compensate the family, and seek a court order obliging the company to obtain the Lacks family’s permission to use the cell line.

“Black people have the right to control their bodies,” civil rights attorney Ben Crump, who is representing the family, says in a statement, The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies